

Development of first-in-class MASTL-targeted drug in triple-negative breast cancer

KIRAMS Oncord bio



ONCOLOGY	Lead
Product Type	Chemical product
Indication	1st Indication: Triple-negative breast cancer overexpressing MASTL (44% genetic amplification) 2nd Indication: Carcinoma overexpressing MASTL (lung cancer, colorectal cancer, etc.)
Target	MASTL
MoA(Mechanism of Action)	MASTL inhibitor - MASTL-PP2A-MYC regulation. 1) Cancer-specific mitotic cell death 2) cancer stem cell 3) mitotic DNA damage induction MOA
Competitiveness	First-in class drug, no competitor drug
Development Stage	Lead
Route of Administration	Optimization